Physician profile
David Ridge
NPI 1942973896
$2,642.45
in general payments reported to CMS, 2019-2025
27 companies · $2,197 in 2025
The $2,197 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $18.21 · 2023: $112 · 2024: $315 · 2025: $2,197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,624.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,624.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $611.31 | 2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $460.01 | 2023-2025 | Airsupra, Lokelma, Breztri |
| Lilly USA, LLC | $258.28 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $203.31 | 2025 | |
| Axsome Therapeutics, INC. | $164.44 | 2025 | Auvelity |
| Amgen INC. | $131.61 | 2024-2025 | Repatha, Krystexxa, Prolia |
| Mallinckrodt Hospital Products INC. | $111.38 | 2024-2025 | Acthar |
| Phathom Pharmaceuticals, INC. | $110.71 | 2025 | Voquezna |
| Ani Pharmaceuticals, INC. | $78.60 | 2024-2025 | Purified Cortrophin Gel |
| Dexcom, INC. | $60.98 | 2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $44.40 | 2025 | Spravato |
| Astellas Pharma US INC | $37.72 | 2025 | Veozah |
| Insulet Corporation | $35.83 | 2023 | Omnipod |
| Travere Therapeutics, INC. | $35.14 | 2024 | |
| Esperion Therapeutics, INC. | $34.79 | 2025 | Nexletol |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $34.60 | 2022-2025 | Vaxelis, Gardasil 9, Capvaxive |
| Teva Pharmaceuticals USA, INC. | $33.81 | 2025 | Austedo Xr, Ajovy |
| Sanofi Pasteur INC. | $30.24 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.49 | 2025 | Glassia |
| Exact Sciences Corporation | $25.98 | 2023 | Cologuard Collection Kit |
| Abbvie INC. | $20.57 | 2025 | |
| Tolmar, INC. | $17.26 | 2025 | Jatenzo |
| Sumitomo Pharma America, INC. | $16.98 | 2025 | Gemtesa |
| Halozyme INC | $16.27 | 2023 | |
| Glaxosmithkline, LLC. | $15.99 | 2025 | Arexvy, Shingrix |
| Corium, LLC | $15.19 | 2025 | Azstarys |
| Cequr Corporation | $8.56 | 2025 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Ridge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.